NCT05583201View on ClinicalTrials.gov

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2026

Conditions
Gastric CancerPancreatic CancerSolid Tumor
Interventions
BIOLOGICAL

KD-496

Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

KAEDI

OTHER

lead

jianming xu

OTHER